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gust 2003 that compared HIV preva-
lence in 426 patients with Buruli 
ulcer and 613 controls in southern Be-
nin, HIV prevalence among patients 
with Buruli ulcer was higher (2.6%, 
11/426) than among controls (0.3%, 
2/613) (odds ratio 8.1) (8). However, 
none of these reported HIV-positive 
patients with Buruli ulcer were treated 
with rifampin/streptomycin and anti-
retroviral therapy (8).
A study of 224 patients with Bu-
ruli ulcer in Benin that evaluated the 
WHO-recommended regimen of 8 
weeks of treatment with rifampin/
streptomycin showed promising re-
sults (9). Chemotherapy alone was 
successful in achieving a cure rate 
of 47% of patients and was effective 
against ulcers <5 cm in diameter (9). 
However, HIV testing was not per-
formed in this study. In Spain, an HIV-
positive patient with aggressive, mul-
tifocal Buruli ulcer and osteomyelitis 
was cured by surgery, broad-spectrum 
antimicrobial drugs (not rifampin/
streptomycin), and antiretroviral drugs 
(10). Relapse was not reported in this 
study at 6-months follow-up.
For control of Buruli ulcer in 
HIV-positive patients, patients should 
be treated with rifampin/streptomycin 
and antiretroviral therapy to stimulate 
their immunity. Our report emphasizes 
the urgent need to evaluate treatment 
of HIV-positive patients infected with 
Buruli ulcer with rifampin/streptomy-
cin and antiretroviral drugs.
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Hantavirus 
Pulmonary 
Syndrome, 
French Guiana
To the Editor: Hantaviruses are 
rodent-borne negative-sense RNA vi-
ruses belonging to the Bunyaviridae 
family, genus Hantavirus. Since the 
ﬁ  rst report of a hantavirus in 1993 in 
the United States (1), different viruses 
belonging to this genus have been re-
ported in the Americas (2–5). These 
New World viruses are responsible for 
a disease called hantavirus pulmonary 
syndrome (HPS), a respiratory ill-
ness caused by the inhalation of dust 
contaminated by rodent feces or urine 
containing the virus (6–8).
Until recently, no information 
was available concerning the presence 
of hantaviruses in French Guiana, a 
French overseas department (admin-
istrative unit) in South America. Nev-
ertheless, the description of atypical 
pneumonia cases not related to any 
known etiologic agent and the iden-
tiﬁ   cation of hantavirus reservoirs in 
neighboring countries led us to con-
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duct a serologic study in a selected 
population of patients with compatible 
symptoms. The prevalence of immu-
noglobulin (Ig) G antibodies to han-
tavirus in this population was 1.42% 
(9). Subsequently, we systematically 
screened patients who had suggestive 
pathologies for hantavirus serology, 
which led us to the characterization of 
a divergent hantavirus.
On August 4, 2008, a 38-year-old 
man sought medical attention at the 
emergency department of Cayenne 
Hospital. He had had persistent symp-
toms of fever (>38.5°C), myalgia, di-
arrhea with melena, cough for 8 days, 
recurrent vomiting for 4 days, and 
dyspnea for 2 days. At consultation, 
tachypnea (respiratory rate 28/min) 
and oxygen desaturation (SaO2 83%) 
were observed. Chest radiograph 
showed bilateral diffuse interstitial 
inﬁ  ltrates causing respiratory distress; 
mechanical ventilation was required. 
The patient was admitted to the inten-
sive care unit for treatment of acute 
respiratory distress syndrome. Results 
of laboratory investigations performed 
when the patient was admitted showed 
thrombocytopenia (50,000 cells/mm3), 
leucocytosis (22,500 cells/mm3) as-
sociated with a high neutrophil count 
(20,300 cells/mm3), moderate hepato-
nephritis (alanine aminotransferase 17 
IU/L, aspartate aminotransferase 31 
IU/L, gamma-glutanyl transferase 44 
IU/L; alkaline phosphatase 44 IU/L; 
creatinine 192 μmol/L and urea 9.3 
mmol/L); and an elevated C-reactive 
protein concentration (>192 mg/L). 
Laboratory tests for infectious agents 
ruled out malaria, dengue, leptospiro-
sis, Chagas disease, Q fever, cytomeg-
alovirus, and HIV, and blood cultures 
were negative for bacterial growth. 
The patient remained under respira-
tory assistance for 25 days in the in-
tensive care unit and was discharged 
from hospital 47 days after admission 
with a complete clinical recovery.
With no etiologic agent identiﬁ  ed, 
2 factors led to the suspicion of han-
tavirus infection: clinical symptoms 
compatible with HPS and the patient’s 
exposure to potential reservoirs. In-
deed, a month before the onset of 
symptoms, he had moved to a rural 
municipality located near agricultural 
lands and forest.
Retrospective serologic inves-
tigations were performed with the 
3 available serum samples obtained 
during the hospitalization. These 
samples were tested by IgM capture 
with inactivated Sin Nombre virus 
antigens and by indirect ELISA with 
recombinant antigens to detect IgG 
antibodies to Sin Nombre virus (10). 
IgM to Sin Nombre virus were pres-
ent in the samples collected 8 and 9 
days, respectively, after onset of the 
disease, conﬁ  rming hantavirus infec-
tion. Furthermore, IgG to Sin Nom-
bre virus were only detected in the 
convalescent-phase serum samples 
obtained on day 41 of the disease. 
These serologic results suggested a 
recent infection with hantavirus.
Molecular investigations were 
performed to characterize and identify 
the virus. Viral RNA was extracted from 
the 2 acute serum samples. Reverse 
transcription–PCR was performed 
with consensus primers targeting the 
S segment of the hantavirus genome 
as described in Johnson et al. (4). 
Ampliﬁ  cation products of the expected 
size (434 bp of the nucleoprotein 
N-encoding region) were obtained 
from both samples. Cloning and 
sequencing of these products allowed 
obtaining a consensus sequence, 
which was deposited with GenBank 
(GQ179973). Database searches using 
BLAST (www.ncbi.nlm.nih.gov/blast) 
demonstrated that this sequence, 
although novel, is most similar to Rio 
Mamore hantavirus strain OM-556 
(GenBank accession no. U52136), 
showing 83% nucleotide identity 
(393 bp analyzed, excluding the 
primers). In addition, comparison with 
representative hantavirus sequences 
from New World isolates showed that 
the ampliﬁ  ed fragment exhibited from 
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Table. Comparison of nucleotide and deduced amino acid sequences between Maripa
virus and representative New World hantaviruses* 
Maripa virus 
% Nucleotide  
sequence identity 
% Amino acid
sequence identity 
RIOM_B 83.0 96.9
RIOM_P 81.9 96.2
ANAJ 81.2 96.2
LAN 81.2 96.2
RIME 77.9 94.7
PARN 78.4 93.9
ARAQ 80.2 93.1
AND 78.6 93.1
ORN 78.4 93.1
MCL 76.8 93.1
CHO 76.1 93.1
PRG 76.6 93.1
LEC 80.2 92.4
BMJ 79.4 92.4
CAD 77.1 92.4
ARAC 77.6 91.6
C_Plata 77.6 90.8
SN 73.5 90.1
*RIOM_B, Rio Mamoré virus strain OM-556 (U52136); RIOM_P, Rio Mamoré virus strain HTN-007 
(AF133254); ANAJ, Anajatuba virus isolate Of58 (DQ451829); LAN, Laguna Negra virus strain 510B 
(AF005727); RIME, Rio Mearim virus isolate Hs85 (DQ451828); PARN, Paranoa virus (EF576661); 
ARAQ, Araraquara virus (AF307325); AND, Andes virus strain AH-1 (AF324902); ORN, Oran virus 
strain 22996, (AF482715); MCL, Maciel virus strain 13796 (AF482716); CHO, Choclo virus (DQ 
285046); PRGm Pergamino virus strain 14403 (AF482717); LEC, Lechiguanas virus strain 22819 
(AF482714); BMJ, Bermejo virus strain Oc22531 (AF482713); CAD, Cano Delgadito virus isolate 
VHV-574 (AF000140); ARAC, Araucaria virus strain HPR/04-102 (AY740633); CAS, Castelo dos 
Sonhos virus (AF307324); C_Plata, Central Plata virus strain 714LC (EU564715); SN, Sin Nombre 
virus strain NM H10 (L25784). LETTERS
73.5% to 81.9% nucleotide sequence 
identity and from 90.1% to 96.9% 
amino acid sequence identity (Table). 
This level of sequence divergence, as 
well as the geographic speciﬁ  city of 
this hantavirus in French Guiana led 
us to provisionally name it Maripa 
virus.
Results of a serologic survey to 
identify cases of respiratory disease 
with no evident etiology led us to 
identify an HPS case-patient in French 
Guiana who had been infected with a 
new divergent hantavirus strain. Hu-
man hantavirus epidemics are associ-
ated with ﬂ  uctuations of rodent popu-
lations caused by climatic, ecologic 
and environmental changes or with 
changes in human activities associated 
with nature or agriculture. Therefore, 
in this region where 90% of the land is 
tropical rain forest but in which there 
is increasing economic development, 
continuous surveillance for the virus 
in the human population would be 
beneﬁ  cial. Surveys of potential reser-
voirs may help reduce the risk of viral 
emergence. 
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Fatal Human 
Case of West Nile 
Virus Disease, 
Mexico, 2009
To the Editor: West Nile virus 
(WNV; family Flaviviridae, genus 
Flavivirus) was ﬁ  rst recognized in the 
Western Hemisphere in 1999 during an 
outbreak of human, equine, and avian 
encephalitis in New York (1). The vi-
rus has since spread across the United 
States and Canada, where it has caused 
≈30,000 human infections and ≈1,000 
deaths. Serologic evidence has demon-
strated that WNV is present throughout 
Mexico, Central America, South Amer-
ica, and the Caribbean region (2–8). 
However, WNV illness in humans and 
vertebrate animals in these regions has 
been only sparsely reported. For in-
stance, 7 human cases of WNV infec-
tion have occurred in Mexico (exclud-
ing the case described here), 3 of which 
were severe. All patients survived. To 
our knowledge, no fatal human cases of 
WNV infection have occurred in Cen-
tral America, South America, or the 
Caribbean region.
We describe a fatal case of WNV 
infection in a human in Central Amer-
ica. The patient, a man 40 years of age, 
lived in Monterrey, Nuevo León State, 
in northern Mexico. He had not trav-
eled outside of the metropolitan area 
in the 6 months before illness onset. 
On June 11, 2009, inﬂ  uenza-like signs 
and symptoms (i.e., fever, malaise, 
fatigue, arthralgia, headache, and diz-
ziness) developed in the patient. On 
June 26, the signs and symptoms had 
not resolved, and the man was admit-
ted to University Hospital “Dr. José 
E. Gonzalez” at the Universidad Au-
tonoma de Nuevo León (UANL). At 
the time of admission, cerebrospinal 
ﬂ  uid (CSF) was collected, and labo-
ratory analysis indicated a markedly 
elevated leukocyte count (182 cells/
mm3; reference range 0–5 cells/mm3) 
and slightly elevated protein and glu-
cose levels.
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